UCL Cancer Institute
The UCL Cancer Institute
The UCL Cancer Institute is the cancer research hub of University College London, one of the world’s leading universities, and is one of the world’s foremost cancer research facilities.
The Institute’s work focuses on research that directly benefits patients with cancer and the work carried out is divided almost equally between basic research, translational research and clinical trials. The Institute is renowned internationally for its major contributions to rare and “difficult to treat” cancers, childhood and early adult cancers, haematological cancers and head and neck cancers.
Much of the current research implements new technologies, such as genetic sequencing and advances in stem cell research, to develop cancer therapies that are personalised to the genetic make-up of each person’s individual tumour so as to maximise the efficacy of the treatment for that individual while minimising harmful toxicity to healthy cells, tissues and organs.
Professor Chris Boshoff FRCP PhD FMedSci
Director, UCL Cancer Institute, and Chair, UCL Cancer Domain
“We are at the dawn of the most exciting time in the history of cancer research and treatment. New targeted therapies are resulting in major clinical responses, and molecular markers, circulating tumour cells, as well as molecular imaging will be applied to stratify patients to the best therapies, sparing patients unnecessary toxic therapies, and facilitating evaluation of responses early during treatment to determine whether patients are responding to specific therapy.
Molecular profiles, including whole genome sequencing information, will determine in the near future the best treatment for each individual patient, as well as helping to predict the likely outcome and adverse affects.”
Page last modified on 21 may 13 10:03